Search hospitals > Quebec > SHERBROOKE
CIUSSS de l'Estrie - CHUS
Claim this profileSHERBROOKE, Quebec J1H 5N4
Conducts research for Crohn's Disease
Conducts research for Ulcerative Colitis
Conducts research for Cancer
Conducts research for Prostate Cancer
Conducts research for Bladder Cancer
45 reported clinical trials
3 medical researchers
Summary
CIUSSS de l'Estrie - CHUS is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Cancer, Prostate Cancer, Bladder Cancer and other specialties. CIUSSS de l'Estrie - CHUS is involved with conducting 45 clinical trials across 103 conditions. There are 3 research doctors associated with this hospital, such as Paul Bessette, MD, Éric Turcotte, MD, and Martin Lepage, PhD.Top PIs
Paul Bessette, MDCHUS - Hôpital Fleurimont5 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
8 reported clinical trials
12 drugs studied
Éric Turcotte, MDCentre de recherche du CHUS1 year of reported clinical research
Studies Traumatic Arthropathy
Studies Bone Cancer
6 reported clinical trials
9 drugs studied
Martin Lepage, PhDDouglas Mental Health University Institute8 years of reported clinical research
Studies Schizophrenia
Studies Psychotic Episodes
6 reported clinical trials
10 drugs studied
Clinical Trials running at CIUSSS de l'Estrie - CHUS
Bladder Cancer
Asthma
Follicular Lymphoma
Endometrial Cancer
Breast Cancer
Thalassemia
Pneumonia
Childhood Asthma
Inflammation
Chronic Kidney Disease
Sacituzumab Tirumotecan
for Bladder Cancer
The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.
Recruiting1 award Phase 1 & 25 criteria
V940 + BCG
for Bladder Cancer
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is not raised and is not growing toward the center of the bladder. The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guerin (BCG). Standard treatment is something that is considered the first line of treatment for a condition. BCG is an immunotherapy, which is a treatment that helps the immune system fight cancer. However, BCG may not work to treat HR NMIBC in some people. Researchers want to learn if adding intismeran autogene, the study treatment, to standard treatment can help treat HR NMIBC. Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goals of this study are to learn: * If people who receive intismeran autogene with BCG live longer without the cancer growing, spreading, or coming back, or dying from any cause, compared to people who receive BCG alone * If more people who receive intismeran autogene with BCG have their cancer go away (complete response), compared to people who receive BCG alone * How many people who receive intismeran autogene without BCG have their cancer go away
Recruiting1 award Phase 25 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CIUSSS de l'Estrie - CHUS?
CIUSSS de l'Estrie - CHUS is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Cancer, Prostate Cancer, Bladder Cancer and other specialties. CIUSSS de l'Estrie - CHUS is involved with conducting 45 clinical trials across 103 conditions. There are 3 research doctors associated with this hospital, such as Paul Bessette, MD, Éric Turcotte, MD, and Martin Lepage, PhD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.